<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:02:19 -0700</creation_date>
  <update_date>2013-01-15 19:02:19 -0700</update_date>
  <accession>HMDBP02078</accession>
  <secondary_accessions>
    <accession>7559</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>ER</synonym>
    <synonym>ER-alpha</synonym>
    <synonym>Estradiol receptor</synonym>
    <synonym>Nuclear receptor subfamily 3 group A member 1</synonym>
  </synonyms>
  <gene_name>ESR1</gene_name>
  <general_function>Involved in sequence-specific DNA binding transcription factor activity</general_function>
  <specific_function>Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Can activate the transcriptional activity of TFF1</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00145</accession>
      <name>Estrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00153</accession>
      <name>Estriol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01939</accession>
      <name>Medroxyprogesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02835</accession>
      <name>Danazol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14400</accession>
      <name>Diethylstilbestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14414</accession>
      <name>Chlorotrianisene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14439</accession>
      <name>Etonogestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14449</accession>
      <name>Desogestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14511</accession>
      <name>Levonorgestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14624</accession>
      <name>Raloxifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14679</accession>
      <name>Toremifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14961</accession>
      <name>Ethynodiol Diacetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15020</accession>
      <name>Clomifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15027</accession>
      <name>Dienestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15082</accession>
      <name>Fulvestrant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15092</accession>
      <name>Norgestimate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01926</accession>
      <name>17a-Ethynylestradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01389</accession>
      <name>Melatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15240</accession>
      <name>Trilostane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15314</accession>
      <name>Naloxone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15316</accession>
      <name>Fluoxymesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15327</accession>
      <name>Estramustine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15446</accession>
      <name>Mestranol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15500</accession>
      <name>Allylestrenol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03217</accession>
      <name>Genistein</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15579</accession>
      <name>Quinestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15658</accession>
      <name>Norelgestromin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>lipid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleic acid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-dependent nuclear receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid hormone receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding transcription factor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of macromolecule metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of gene expression</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription, dna-dependent</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>nucleus</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Nucleus</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:6</chromosome_location>
    <locus>6q25.1</locus>
    <gene_sequence>&gt;1788 bp
ATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCAAGGG
AACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGC
GAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTAC
GAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTAC
GGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCTGGGGGGTTTCCCCCCACTC
AACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC
CTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACG
GTGCGCGAGGCCGGCCCGCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGT
GGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAG
GAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGG
TCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG
TGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGC
CGGCTCCGCAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGA
GGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTG
GGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGC
TCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTG
GATGCTGAGCCCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCT
TCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGG
GCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAA
TGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGTG
AAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGC
ATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTG
CAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACA
TTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGAC
AAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAG
CACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAA
GGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTG
CTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAA
AAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACAGTCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>595</residue_number>
    <molecular_weight>66215.4</molecular_weight>
    <theoretical_pi>8.14</theoretical_pi>
    <pfams>
      <pfam>
        <name>Hormone_recep</name>
        <pfam_id>PF00104</pfam_id>
      </pfam>
      <pfam>
        <name>Oest_recep</name>
        <pfam_id>PF02159</pfam_id>
      </pfam>
      <pfam>
        <name>zf-C4</name>
        <pfam_id>PF00105</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>None</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Estrogen receptor
MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAY
EFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPF
LQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAK
ETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
RLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKR
SKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINW
AKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEG
MVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLD
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLL
LEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>31234</genbank_protein_id>
  <uniprot_id>P03372</uniprot_id>
  <uniprot_name>ESR1_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1R5K</pdb_id>
  </pdb_ids>
  <genbank_gene_id>X03635</genbank_gene_id>
  <genecard_id>ESR1</genecard_id>
  <geneatlas_id>ESR1</geneatlas_id>
  <hgnc_id>HGNC:3467</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986 Mar 13-19;320(6058):134-9.</reference_text>
      <pubmed_id>3754034</pubmed_id>
    </reference>
    <reference>
      <reference_text>Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J: Sequence and expression of human estrogen receptor complementary DNA.  Science. 1986 Mar 7;231(4742):1150-4.</reference_text>
      <pubmed_id>3753802</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC: A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 1996 Mar 1;24(5):962-9.</reference_text>
      <pubmed_id>8600466</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6.  Nature. 2003 Oct 23;425(6960):805-11.</reference_text>
      <pubmed_id>14574404</pubmed_id>
    </reference>
    <reference>
      <reference_text>Joel PB, Traish AM, Lannigan DA: Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol. 1995 Aug;9(8):1041-52.</reference_text>
      <pubmed_id>7476978</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schubert EL, Lee MK, Newman B, King MC: Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7.</reference_text>
      <pubmed_id>10619354</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pfeffer U, Fecarotta E, Castagnetta L, Vidali G: Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res. 1993 Feb 15;53(4):741-3.</reference_text>
      <pubmed_id>7916651</pubmed_id>
    </reference>
    <reference>
      <reference_text>Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol. 1995 Jan;9(1):24-33.</reference_text>
      <pubmed_id>7539106</pubmed_id>
    </reference>
    <reference>
      <reference_text>Reese JC, Katzenellenbogen BS: Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. J Biol Chem. 1992 May 15;267(14):9868-73.</reference_text>
      <pubmed_id>1577818</pubmed_id>
    </reference>
    <reference>
      <reference_text>Arnold SF, Obourn JD, Jaffe H, Notides AC: Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol. 1994 Sep;8(9):1208-14.</reference_text>
      <pubmed_id>7838153</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jiang MS, Hart GW: A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem. 1997 Jan 24;272(4):2421-8.</reference_text>
      <pubmed_id>8999954</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O, Pagliai K, Gray K, Gutkind S, Segars J: Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action. Oncogene. 1998 May 14;16(19):2513-26.</reference_text>
      <pubmed_id>9627117</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999 Aug 6;274(32):22296-302.</reference_text>
      <pubmed_id>10428798</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW: A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem. 1999 Nov 26;274(48):34283-93.</reference_text>
      <pubmed_id>10567404</pubmed_id>
    </reference>
    <reference>
      <reference_text>Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6947-52.</reference_text>
      <pubmed_id>10359819</pubmed_id>
    </reference>
    <reference>
      <reference_text>Abramovich C, Shen WF, Pineault N, Imren S, Montpetit B, Largman C, Humphries RK: Functional cloning and characterization of a novel nonhomeodomain protein that inhibits the binding of PBX1-HOX complexes to DNA. J Biol Chem. 2000 Aug 25;275(34):26172-7.</reference_text>
      <pubmed_id>10825160</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chan SW, Hong W: Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone receptor-mediated transcription. J Biol Chem. 2001 Jul 27;276(30):28402-12. Epub 2001 May 17.</reference_text>
      <pubmed_id>11358960</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001 Jan;21(1):343-53.</reference_text>
      <pubmed_id>11113208</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shao W, Halachmi S, Brown M: ERAP140, a conserved tissue-specific nuclear receptor coactivator.  Mol Cell Biol. 2002 May;22(10):3358-72.</reference_text>
      <pubmed_id>11971969</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1.</reference_text>
      <pubmed_id>12415108</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK: BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol. 2003 Sep;23(17):6210-20.</reference_text>
      <pubmed_id>12917342</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bu H, Kashireddy P, Chang J, Zhu YT, Zhang Z, Zheng W, Rao SM, Zhu YJ: ERBP, a novel estrogen receptor binding protein enhancing the activity of estrogen receptor. Biochem Biophys Res Commun. 2004 Apr 23;317(1):54-9.</reference_text>
      <pubmed_id>15047147</pubmed_id>
    </reference>
    <reference>
      <reference_text>Damdimopoulos AE, Miranda-Vizuete A, Treuter E, Gustafsson JA, Spyrou G: An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling. J Biol Chem. 2004 Sep 10;279(37):38721-9. Epub 2004 Jun 14.</reference_text>
      <pubmed_id>15199063</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rayala SK, den Hollander P, Balasenthil S, Yang Z, Broaddus RR, Kumar R: Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep. 2005 Jun;6(6):538-44.</reference_text>
      <pubmed_id>15891768</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM: The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene. 2005 Aug 25;24(36):5576-88.</reference_text>
      <pubmed_id>15940264</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mo R, Rao SM, Zhu YJ: Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem. 2006 Jun 9;281(23):15714-20. Epub 2006 Apr 7.</reference_text>
      <pubmed_id>16603732</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rayala SK, den Hollander P, Manavathi B, Talukder AH, Song C, Peng S, Barnekow A, Kremerskothen J, Kumar R: Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells. J Biol Chem. 2006 Jul 14;281(28):19092-9. Epub 2006 May 9.</reference_text>
      <pubmed_id>16684779</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wei X, Xu H, Kufe D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.  Mol Cell. 2006 Jan 20;21(2):295-305.</reference_text>
      <pubmed_id>16427018</pubmed_id>
    </reference>
    <reference>
      <reference_text>Eriksson M, Samuelsson H, Samuelsson EB, Liu L, McKeehan WL, Benedikz E, Sundstrom E: The NMDAR subunit NR3A interacts with microtubule-associated protein 1S in the brain. Biochem Biophys Res Commun. 2007 Sep 14;361(1):127-32. Epub 2007 Jul 16.</reference_text>
      <pubmed_id>17658481</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, Pan X, Li AL, Gong WL, Jin BF, Xia Q, Yu M, Shen BF, Zhang XM: CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 2007 Apr 4;26(7):1831-42. Epub 2007 Mar 8.</reference_text>
      <pubmed_id>17347654</pubmed_id>
    </reference>
    <reference>
      <reference_text>Han WD, Zhao YL, Meng YG, Zang L, Wu ZQ, Li Q, Si YL, Huang K, Ba JM, Morinaga H, Nomura M, Mu YM: Estrogenically regulated LRP16 interacts with estrogen receptor alpha and enhances the receptor's transcriptional activity. Endocr Relat Cancer. 2007 Sep;14(3):741-53.</reference_text>
      <pubmed_id>17914104</pubmed_id>
    </reference>
    <reference>
      <reference_text>Luboshits G, Benayahu D: MS-KIF18A, a kinesin, is associated with estrogen receptor.  J Cell Biochem. 2007 Feb 15;100(3):693-702.</reference_text>
      <pubmed_id>17006958</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yan J, Kim YS, Yang XP, Albers M, Koegl M, Jetten AM: Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor alpha. Nucleic Acids Res. 2007;35(5):1673-86. Epub 2007 Feb 20.</reference_text>
      <pubmed_id>17311814</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW: ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18067-72. Epub 2007 Nov 12.</reference_text>
      <pubmed_id>17998543</pubmed_id>
    </reference>
    <reference>
      <reference_text>Imami K, Sugiyama N, Kyono Y, Tomita M, Ishihama Y: Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column. Anal Sci. 2008 Jan;24(1):161-6.</reference_text>
      <pubmed_id>18187866</pubmed_id>
    </reference>
    <reference>
      <reference_text>Li T, Li W, Lu J, Liu H, Li Y, Zhao Y: SH2D4A regulates cell proliferation via the ERalpha/PLC-gamma/PKC pathway.  BMB Rep. 2009 Aug 31;42(8):516-22.</reference_text>
      <pubmed_id>19712589</pubmed_id>
    </reference>
    <reference>
      <reference_text>Johnsen SA, Gungor C, Prenzel T, Riethdorf S, Riethdorf L, Taniguchi-Ishigaki N, Rau T, Tursun B, Furlow JD, Sauter G, Scheffner M, Pantel K, Gannon F, Bach I: Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res. 2009 Jan 1;69(1):128-36.</reference_text>
      <pubmed_id>19117995</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stanisic V, Malovannaya A, Qin J, Lonard DM, O'Malley BW: OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J Biol Chem. 2009 Jun 12;284(24):16135-45. Epub 2009 Apr 21.</reference_text>
      <pubmed_id>19383985</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zusev M, Benayahu D: The regulation of MS-KIF18A expression and cross talk with estrogen receptor. PLoS One. 2009 Jul 28;4(7):e6407.</reference_text>
      <pubmed_id>19636373</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schwabe JW, Neuhaus D, Rhodes D: Solution structure of the DNA-binding domain of the oestrogen receptor.  Nature. 1990 Nov 29;348(6300):458-61.</reference_text>
      <pubmed_id>2247153</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schwabe JW, Chapman L, Finch JT, Rhodes D: The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell. 1993 Nov 5;75(3):567-78.</reference_text>
      <pubmed_id>8221895</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor.  Nature. 1997 Oct 16;389(6652):753-8.</reference_text>
      <pubmed_id>9338790</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tanenbaum DM, Wang Y, Williams SP, Sigler PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A. 1998 May 26;95(11):5998-6003.</reference_text>
      <pubmed_id>9600906</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7):927-37.</reference_text>
      <pubmed_id>9875847</pubmed_id>
    </reference>
    <reference>
      <reference_text>Maalouf GJ, Xu W, Smith TF, Mohr SC: Homology model for the ligand-binding domain of the human estrogen receptor. J Biomol Struct Dyn. 1998 Apr;15(5):841-51.</reference_text>
      <pubmed_id>9619507</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989 Jul;8(7):1981-6.</reference_text>
      <pubmed_id>2792078</pubmed_id>
    </reference>
    <reference>
      <reference_text>McInerney EM, Ince BA, Shapiro DJ, Katzenellenbogen BS: A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. Mol Endocrinol. 1996 Dec;10(12):1519-26.</reference_text>
      <pubmed_id>8961262</pubmed_id>
    </reference>
    <reference>
      <reference_text>Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Moller P, Stratton MR, Borresen-Dale AL: Screening for ESR mutations in breast and ovarian cancer patients.  Hum Mutat. 1997;9(6):531-6.</reference_text>
      <pubmed_id>9195227</pubmed_id>
    </reference>
    <reference>
      <reference_text>Becherini L, Gennari L, Masi L, Mansani R, Massart F, Morelli A, Falchetti A, Gonnelli S, Fiorelli G, Tanini A, Brandi ML: Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet. 2000 Aug 12;9(13):2043-50.</reference_text>
      <pubmed_id>10942433</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Borresen-Dale AL: Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res. 2007;9(1):R5.</reference_text>
      <pubmed_id>17224074</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, d'Abusco AS, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27.</reference_text>
        <pubmed_id>17125913</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: THE EFFECT OF ESTRADIOL ON IN VIVO TUMORIGENESIS IS MODULATED BY THE ErbB2/PI 3-K/Akt1 PATHWAY. Endocrinology. 2006 Nov 30;.</reference_text>
        <pubmed_id>17138652</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69.</reference_text>
        <pubmed_id>2011412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estriol</name>
        <accession>HMDB00153</accession>
      </metabolite>
      <reference>
        <reference_text>Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69.</reference_text>
        <pubmed_id>2011412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estriol</name>
        <accession>HMDB00153</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology.  Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14.</reference_text>
        <pubmed_id>17103262</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women.  Reprod Biol Endocrinol. 2006;4 Suppl 1:S9.</reference_text>
        <pubmed_id>17118173</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36.</reference_text>
        <pubmed_id>17203775</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22.</reference_text>
        <pubmed_id>17341305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8.</reference_text>
        <pubmed_id>17415709</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Munoz G, Ovilo C, Estelle J, Silio L, Fernandez A, Rodriguez C: Association with litter size of new polymorphisms on ESR1 and ESR2 genes in a Chinese-European pig line. Genet Sel Evol. 2007 Mar-Apr;39(2):195-206. Epub 2007 Feb 17.</reference_text>
        <pubmed_id>17306201</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Dixon A, Wells CC, Singh S, Babayan R, Maric C: Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol. 2007;27(2):120-8. Epub 2007 Feb 15.</reference_text>
        <pubmed_id>17308373</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Hart SA, Snyder MA, Smejkalova T, Woolley CS: Estrogen mobilizes a subset of estrogen receptor-alpha-immunoreactive vesicles in inhibitory presynaptic boutons in hippocampal CA1. J Neurosci. 2007 Feb 21;27(8):2102-11.</reference_text>
        <pubmed_id>17314305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Baron S, Escande A, Alberola G, Bystricky K, Balaguer P, Richard-Foy H: Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene. J Biol Chem. 2007 Apr 20;282(16):11732-41. Epub 2007 Feb 22.</reference_text>
        <pubmed_id>17317669</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Bains M, Cousins JC, Roberts JL: Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp Neurol. 2007 Apr;204(2):767-76. Epub 2007 Jan 25.</reference_text>
        <pubmed_id>17320868</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Kwok KC, Cheung NH: Measuring binding kinetics of ligands with tethered receptors by fluorescence polarization and total internal reflection fluorescence. Anal Chem. 2010 May 1;82(9):3819-25.</reference_text>
        <pubmed_id>20387803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorotrianisene</name>
        <accession>HMDB14414</accession>
      </metabolite>
      <reference>
        <reference_text>Kupfer D, Bulger WH: Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). Speculation that TACE antiestrogenic activity involves covalent binding to the estrogen receptor. FEBS Lett. 1990 Feb 12;261(1):59-62.</reference_text>
        <pubmed_id>2307235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorotrianisene</name>
        <accession>HMDB14414</accession>
      </metabolite>
      <reference>
        <reference_text>Jordan VC, Gosden B: Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology. 1983 Aug;113(2):463-8.</reference_text>
        <pubmed_id>6872937</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorotrianisene</name>
        <accession>HMDB14414</accession>
      </metabolite>
      <reference>
        <reference_text>Wang JY, Xu BH, Tian LJ, Wang Y: [Clinical characteristics and potential prognostic factors of breast cancer patients with liver metastases]. Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):612-6.</reference_text>
        <pubmed_id>17236558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorotrianisene</name>
        <accession>HMDB14414</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Fuhrmann U, Slater EP, Fritzemeier KH: Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception. 1995 Jan;51(1):45-52.</reference_text>
        <pubmed_id>7750284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Rabe T, Bohlmann MK, Rehberger-Schneider S, Prifti S: Induction of estrogen receptor-alpha and -beta activities by synthetic progestins. Gynecol Endocrinol. 2000 Apr;14(2):118-26.</reference_text>
        <pubmed_id>10836199</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desogestrel</name>
        <accession>HMDB14449</accession>
      </metabolite>
      <reference>
        <reference_text>Juchem M, Pollow K: Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2171-83.</reference_text>
        <pubmed_id>2175153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Vereide AB, Kaino T, Sager G, Arnes M, Orbo A: Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006 May;101(2):214-23. Epub 2005 Dec 1.</reference_text>
        <pubmed_id>16325240</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Mirkin S, Wong BC, Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005 Aug;84(2):485-91.</reference_text>
        <pubmed_id>16084894</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM: Tamoxifen treatment of bleeding irregularities associated with Norplant use.  Contraception. 2005 Dec;72(6):432-7. Epub 2005 Aug 9.</reference_text>
        <pubmed_id>16307966</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Sun D, Yan C, Jacobson A, Jiang H, Carroll MA, Huang A: Contribution of epoxyeicosatrienoic acids to flow-induced dilation in arteries of male ERalpha knockout mice: role of aromatase. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1239-46. Epub 2007 Jul       18.</reference_text>
        <pubmed_id>17634204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Vijayanathan V, Venkiteswaran S, Nair SK, Verma A, Thomas TJ, Zhu BT, Thomas T: Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2038-48.</reference_text>
        <pubmed_id>16609013</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women.  Ann Intern Med. 1999 Mar 2;130(5):431-9.</reference_text>
        <pubmed_id>10068418</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999 Jun 16;281(23):2189-97.</reference_text>
        <pubmed_id>10376571</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Bryant HU, Glasebrook AL, Yang NN, Sato M: An estrogen receptor basis for raloxifene action in bone.  J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):37-44.</reference_text>
        <pubmed_id>10418979</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Figtree GA, Lu Y, Webb CM, Collins P: Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 1999 Sep 7;100(10):1095-101.</reference_text>
        <pubmed_id>10477535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Schafer JI, Liu H, Tonetti DA, Jordan VC: The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res. 1999 Sep 1;59(17):4308-13.</reference_text>
        <pubmed_id>10485477</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Scott JA, Da Camara CC, Early JE: Raloxifene: a selective estrogen receptor modulator.  Am Fam Physician. 1999 Sep 15;60(4):1131-9.</reference_text>
        <pubmed_id>10507743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Matsumoto T: [Selective estrogen receptor modulators (SERMs)].  Clin Calcium. 2006 Sep;16(9):1520-25.</reference_text>
        <pubmed_id>16951478</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Moen MD, Keating GM: Raloxifene: a review of its use in the prevention of invasive breast cancer.  Drugs. 2008;68(14):2059-83.</reference_text>
        <pubmed_id>18778124</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Locci P, Bellocchio S, Lilli C, Marinucci L, Cagini L, Baroni T, Giustozzi G, Balducci C, Becchetti E: Synthesis and secretion of transforming growth factor-beta1 by human desmoid fibroblast cell line and its modulation by toremifene. J Interferon Cytokine Res. 2001 Nov;21(11):961-70.</reference_text>
        <pubmed_id>11747628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL: Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem Res Toxicol. 2003 Jul;16(7):832-7.</reference_text>
        <pubmed_id>12870885</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Jones KL, Buzdar AU: A review of adjuvant hormonal therapy in breast cancer.  Endocr Relat Cancer. 2004 Sep;11(3):391-406.</reference_text>
        <pubmed_id>15369444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB: Selective estrogen receptor modulators: an update on recent clinical findings.  Obstet Gynecol Surv. 2008 Mar;63(3):163-81.</reference_text>
        <pubmed_id>18279543</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R: Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24(5):361-79.</reference_text>
        <pubmed_id>17503894</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Lewis-Wambi JS, Jordan VC: Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis. 2005-2006;24:93-105.</reference_text>
        <pubmed_id>16917142</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Ariazi EA, Ariazi JL, Cordera F, Jordan VC: Estrogen receptors as therapeutic targets in breast cancer.  Curr Top Med Chem. 2006;6(3):181-202.</reference_text>
        <pubmed_id>16515478</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA: Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar;15(3):293-305.</reference_text>
        <pubmed_id>16503765</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Goldstein LJ: Controversies in adjuvant endocrine treatment of premenopausal women.  Clin Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.</reference_text>
        <pubmed_id>16595024</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Smith MR: Treatment-related osteoporosis in men with prostate cancer.  Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6315s-6319s.</reference_text>
        <pubmed_id>17062721</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69.</reference_text>
        <pubmed_id>2011412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Fabian CJ, Kimler BF: Chemoprevention for high-risk women: tamoxifen and beyond.  Breast J. 2001 Sep-Oct;7(5):311-20.</reference_text>
        <pubmed_id>11906441</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Cyrus K, Wehenkel M, Choi EY, Lee H, Swanson H, Kim KB: Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem. 2010 Jul 5;5(7):979-85.</reference_text>
        <pubmed_id>20512796</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethynodiol Diacetate</name>
        <accession>HMDB14961</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethynodiol Diacetate</name>
        <accession>HMDB14961</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethynodiol Diacetate</name>
        <accession>HMDB14961</accession>
      </metabolite>
      <reference>
        <reference_text>Kappus H, Bolt HM, Remmer H: Affinity of ethynyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. J Steroid Biochem. 1973 Mar;4(2):121-8.</reference_text>
        <pubmed_id>4123746</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69.</reference_text>
        <pubmed_id>2011412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Kurosawa T, Hiroi H, Momoeda M, Inoue S, Taketani Y: Clomiphene citrate elicits estrogen agonistic/antagonistic effects differentially via estrogen receptors alpha and beta. Endocr J. 2010;57(6):517-21. Epub 2010 Apr 6.</reference_text>
        <pubmed_id>20379036</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Hughes E, Brown J, Collins JJ, Vanderkerchove P: Clomiphene citrate for unexplained subfertility in women.  Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000057.</reference_text>
        <pubmed_id>20091498</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E: Clomiphene and anti-oestrogens for ovulation induction in PCOS.  Cochrane Database Syst Rev. 2009 Oct 7;(4):CD002249.</reference_text>
        <pubmed_id>19821295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Use of clomiphene citrate in women.  Fertil Steril. 2006 Nov;86(5 Suppl 1):S187-93.</reference_text>
        <pubmed_id>17055820</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Overbeek A, Lambalk N: Pharmacogenomics of ovulation induction: facilitating decisions on who, when and how to treat. Pharmacogenomics. 2009 Sep;10(9):1377-9.</reference_text>
        <pubmed_id>19761360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Homburg R: Oral agents for ovulation induction--clomiphene citrate versus aromatase inhibitors. Hum Fertil (Camb). 2008 Mar;11(1):17-22.</reference_text>
        <pubmed_id>18320435</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Homburg R: Clomiphene citrate--end of an era? A mini-review.  Hum Reprod. 2005 Aug;20(8):2043-51. Epub 2005 May 5.</reference_text>
        <pubmed_id>15878925</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Juriansz RL, Huseby RA, Wilcox RB: Interactions of putative estrogens with the intracellular receptor complex in mouse Leydig cells: relationship to preneoplastic hyperplasia. Cancer Res. 1988 Jan 1;48(1):14-8.</reference_text>
        <pubmed_id>3334987</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Grove RI, Korach KS: Estrogen stimulation of phosphatidylinositol metabolism in mouse uterine tissue.  Endocrinology. 1987 Sep;121(3):1083-8.</reference_text>
        <pubmed_id>3622377</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997 Mar;138(3):863-70.</reference_text>
        <pubmed_id>9048584</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Chae K, Lindzey J, McLachlan JA, Korach KS: Estrogen-dependent gene regulation by an oxidative metabolite of diethylstilbestrol, diethylstilbestrol-4',4"-quinone. Steroids. 1998 Mar;63(3):149-57.</reference_text>
        <pubmed_id>9558716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Bovee TF, Helsdingen RJ, Rietjens IM, Keijer J, Hoogenboom RL: Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol. 2004 Jul;91(3):99-109.</reference_text>
        <pubmed_id>15276617</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Maru BS, Tobias JH, Rivers C, Caunt CJ, Norman MR, McArdle CA: Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12. Epub 2008 Oct 11.</reference_text>
        <pubmed_id>18976723</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dienestrol</name>
        <accession>HMDB15027</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Curran M, Wiseman L: Fulvestrant.  Drugs. 2001;61(6):807-13; discussion 814.</reference_text>
        <pubmed_id>11398912</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Elkak AE, Mokbel K: Pure antiestrogens and breast cancer.  Curr Med Res Opin. 2001;17(4):282-9.</reference_text>
        <pubmed_id>11922402</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Dow KH: Existing and emerging endocrine therapies for breast cancer.  Cancer Nurs. 2002 Apr;25 Suppl 2:6S-11S.</reference_text>
        <pubmed_id>12080538</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Bundred N, Howell A: Fulvestrant (Faslodex): current status in the therapy of breast cancer.  Expert Rev Anticancer Ther. 2002 Apr;2(2):151-60.</reference_text>
        <pubmed_id>12113237</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Morris C, Wakeling A: Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer. 2002 Dec;9(4):267-76.</reference_text>
        <pubmed_id>12542403</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Kabos P, Borges VF: Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.  Expert Opin Pharmacother. 2010 Apr;11(5):807-16.</reference_text>
        <pubmed_id>20151846</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>McKeage K, Curran MP, Plosker GL: Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs. 2004;64(6):633-48.</reference_text>
        <pubmed_id>15018596</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Jones SE, Pippen J: Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2005 Apr;6 Suppl 1:S9-14.</reference_text>
        <pubmed_id>15865850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Pasqualini JR: Differential effects of progestins on breast tissue enzymes.  Maturitas. 2003 Dec 10;46 Suppl 1:S45-54.</reference_text>
        <pubmed_id>14670645</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Juchem M, Pollow K: Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2171-83.</reference_text>
        <pubmed_id>2175153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norgestimate</name>
        <accession>HMDB15092</accession>
      </metabolite>
      <reference>
        <reference_text>Shields-Botella J, Duc I, Duranti E, Puccio F, Bonnet P, Delansorne R, Paris J: An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells. J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):111-22.</reference_text>
        <pubmed_id>14672731</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K: Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures.  Endocrinology. 2007 Feb;148(2):782-9. Epub 2006 Nov 9.</reference_text>
        <pubmed_id>17095591</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Garcia-Segura LM, Sanz A, Mendez P: Cross-Talk between IGF-I and Estradiol in the Brain: Focus on Neuroprotection. Neuroendocrinology. 2006 Nov 23;.</reference_text>
        <pubmed_id>17124377</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, d'Abusco AS, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27.</reference_text>
        <pubmed_id>17125913</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: THE EFFECT OF ESTRADIOL ON IN VIVO TUMORIGENESIS IS MODULATED BY THE ErbB2/PI 3-K/Akt1 PATHWAY. Endocrinology. 2006 Nov 30;.</reference_text>
        <pubmed_id>17138652</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Mukai H, Tsurugizawa T, Ogiue-Ikeda M, Murakami G, Hojo Y, Ishii H, Kimoto T, Kawato S: Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory. Neuroendocrinology. 2006;84(4):255-63. Epub 2006 Dec 1.</reference_text>
        <pubmed_id>17142999</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Notch EG, Mayer GD: 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. Epub 2009 Jan 23.</reference_text>
        <pubmed_id>19237207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Bennink HJ: Reprint of Are all estrogens the same?  Maturitas. 2008 Sep-Oct;61(1-2):195-201.</reference_text>
        <pubmed_id>19434891</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S: Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem. 2004 Sep 10;279(37):38294-302. Epub 2004 Jun 30.</reference_text>
        <pubmed_id>15229223</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Yoo YM, Jeung EB: Melatonin-induced estrogen receptor alpha-mediated calbindin-D9k expression plays a role in H2O2-mediated cell death in rat pituitary GH3 cells. J Pineal Res. 2009 Nov;47(4):301-7. Epub 2009 Oct 1.</reference_text>
        <pubmed_id>19796047</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trilostane</name>
        <accession>HMDB15240</accession>
      </metabolite>
      <reference>
        <reference_text>Puddefoot JR, Barker S, Vinson GP: Trilostane in advanced breast cancer.  Expert Opin Pharmacother. 2006 Dec;7(17):2413-9.</reference_text>
        <pubmed_id>17109615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trilostane</name>
        <accession>HMDB15240</accession>
      </metabolite>
      <reference>
        <reference_text>Puddefoot JR, Barker S, Glover HR, Malouitre SD, Vinson GP: Non-competitive steroid inhibition of oestrogen receptor functions.  Int J Cancer. 2002 Sep 1;101(1):17-22.</reference_text>
        <pubmed_id>12209583</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trilostane</name>
        <accession>HMDB15240</accession>
      </metabolite>
      <reference>
        <reference_text>Barker S, Malouitre SD, Glover HR, Puddefoot JR, Vinson GP: Comparison of effects of 4-hydroxy tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):141-51. Epub 2006 Jun 27.</reference_text>
        <pubmed_id>16806905</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K: Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells.  Mol Cancer Ther. 2006 Mar;5(3):611-20.</reference_text>
        <pubmed_id>16546975</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluoxymesterone</name>
        <accession>HMDB15316</accession>
      </metabolite>
      <reference>
        <reference_text>Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul;98(2):217-22. Epub 2006 Mar 15.</reference_text>
        <pubmed_id>16538529</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluoxymesterone</name>
        <accession>HMDB15316</accession>
      </metabolite>
      <reference>
        <reference_text>Sledge GW Jr, Hu P, Falkson G, Tormey D, Abeloff M: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 2000 Jan;18(2):262-6.</reference_text>
        <pubmed_id>10637238</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluoxymesterone</name>
        <accession>HMDB15316</accession>
      </metabolite>
      <reference>
        <reference_text>Pearson OH, Manni A, Arafah BM: Antiestrogen treatment of breast cancer: an overview.  Cancer Res. 1982 Aug;42(8 Suppl):3424s-3429s.</reference_text>
        <pubmed_id>7044524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluoxymesterone</name>
        <accession>HMDB15316</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May;14(5):1589-98.</reference_text>
        <pubmed_id>8622076</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluoxymesterone</name>
        <accession>HMDB15316</accession>
      </metabolite>
      <reference>
        <reference_text>Swain SM, Steinberg SM, Bagley C, Lippman ME: Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study. Breast Cancer Res Treat. 1988 Sep;12(1):51-7.</reference_text>
        <pubmed_id>3058238</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Ferno M, Borg A, Ingvar C, Jonsson PE: Estrogen receptor and binding site for estramustine in metastatic malignant melanoma. Anticancer Res. 1987 Jul-Aug;7(4B):741-3.</reference_text>
        <pubmed_id>3314674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Yoshizumi N: [The effects of site-directed chemotherapy due to E2 as a drug carrier to the human endometrial adenocarcinoma cells in vitro]. Nihon Sanka Fujinka Gakkai Zasshi. 1985 Apr;37(4):637-45.</reference_text>
        <pubmed_id>3989343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>von Schoultz E, Carlstrom K, Henriksson R, Lagerlof B, Hansson J: Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.</reference_text>
        <pubmed_id>7703721</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Tew KD: The mechanism of action of estramustine.  Semin Oncol. 1983 Sep;10(3 Suppl 3):21-6.</reference_text>
        <pubmed_id>6364362</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mestranol</name>
        <accession>HMDB15446</accession>
      </metabolite>
      <reference>
        <reference_text>Dulos J, Vijn P, van Doorn C, Hofstra CL, Veening-Griffioen D, de Graaf J, Dijcks FA, Boots AM: Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor alpha but not estrogen receptor beta. Arthritis Res Ther. 2010;12(3):R101. Epub 2010 May 24.</reference_text>
        <pubmed_id>20497523</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mestranol</name>
        <accession>HMDB15446</accession>
      </metabolite>
      <reference>
        <reference_text>Cleuren AC, Van der Linden IK, De Visser YP, Wagenaar GT, Reitsma PH, Van Vlijmen BJ: 17alpha-Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor alpha. J Thromb Haemost. 2010 Aug;8(8):1838-46. doi: 10.1111/j.1538-7836.2010.03930.x.       Epub 2010 May 27.</reference_text>
        <pubmed_id>20524981</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mestranol</name>
        <accession>HMDB15446</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology.  Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14.</reference_text>
        <pubmed_id>17103262</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women.  Reprod Biol Endocrinol. 2006;4 Suppl 1:S9.</reference_text>
        <pubmed_id>17118173</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36.</reference_text>
        <pubmed_id>17203775</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22.</reference_text>
        <pubmed_id>17341305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8.</reference_text>
        <pubmed_id>17415709</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Csaba G, Gonda AI, Karabelyos C: Contraceptive treatment increases the affinity of uterine estrogen receptor in adult rat: perinatal gestagen treatment changes the reaction. Horm Metab Res. 1996 Jan;28(1):16-9.</reference_text>
        <pubmed_id>8820988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinestrol</name>
        <accession>HMDB15579</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinestrol</name>
        <accession>HMDB15579</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinestrol</name>
        <accession>HMDB15579</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinestrol</name>
        <accession>HMDB15579</accession>
      </metabolite>
      <reference>
        <reference_text>Shyu C, Cavileer TD, Nagler JJ, Ytreberg FM: Computational estimation of rainbow trout estrogen receptor binding affinities for environmental estrogens. Toxicol Appl Pharmacol. 2011 Feb 1;250(3):322-6. Epub 2010 Nov 12.</reference_text>
        <pubmed_id>21075131</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Pasqualini JR: Differential effects of progestins on breast tissue enzymes.  Maturitas. 2003 Dec 10;46 Suppl 1:S45-54.</reference_text>
        <pubmed_id>14670645</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Juchem M, Pollow K: Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2171-83.</reference_text>
        <pubmed_id>2175153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norelgestromin</name>
        <accession>HMDB15658</accession>
      </metabolite>
      <reference>
        <reference_text>Shields-Botella J, Duc I, Duranti E, Puccio F, Bonnet P, Delansorne R, Paris J: An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells. J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):111-22.</reference_text>
        <pubmed_id>14672731</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
